Skip to main content

Development of Functionalised Cell Seeded Bioartificial Organ for Transplantation in Nerve Repair

Objetivo

Injuries and degenerative diseases of the central nervous system constitute a bottleneck in medical and surgical practice for which no therapy currently exists. To ensure clinical translation, NeuroGraft is organised in three R&D Work-Packages. NeuroGraft will develop functionalised cell seeded bioartificial organs, specifically spinal cord conduits for transplantation, incorporating a potent immunomodulatory cytokine (IL37) to target the initial inflammatory response to increase the survival and therapeutic efficacy of transplanted mesenchymal cells and the expression of potent neuro-regulatory molecules for enhanced functional nerve regeneration in the central nervous system.
This exciting concept will be realised through the NeuroGraft consortium, consisting of one academic and four industrial partners (all SMEs), across four countries, with distinct synergistic expertise (including regulatory expertise) to develop cell seeded functionalised bioartificial organs as valuable solutions towards spinal cord repair. Regulatory advice is incorporated at an early stage in the development cycle, to facilitate the translation of the novel bioartificial devices developed, to the market in as short a timeframe as possible. The NeuroGraft consortium will validate the safety, efficacy and biodistribution of the functionalised bioartificial organs developed in a pre-clinical model of spinal cord under GLP conditions. Full Quality Assurance reports will be completed towards CE Mark regulatory approval of the medical device for spinal cord repair. These studies will facilitate progression to clinical trials of the technology (post project) and the development of a marketable product within 6 years of the completion of the NeuroGraft project. Intellectual property will be patented ensuring that SME’s have veto rights on commercial route for exploitation. An extensive business plan outlining detailed valorisation plan is presented.

Convocatoria de propuestas

FP7-HEALTH-2012-INNOVATION-2
Consulte otros proyectos de esta convocatoria

Coordinador

NATIONAL UNIVERSITY OF IRELAND GALWAY
Dirección
University Road
H91 Galway
Irlanda

Ver en el mapa

Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Mari Vahey (Ms.)
Aportación de la UE
€ 1 347 138,24

Participantes (4)

ASHLAND SPECIALTIES IRELAND LIMITED
Irlanda
Aportación de la UE
€ 797 383,60
Dirección
National Science Park, Building V, Dublin Road, Petitswood
N91 F6PD Mullingar, Westmeath

Ver en el mapa

Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
Colm O'dowd (Dr.)
STEMMATTERS, BIOTECNOLOGIA E MEDICIINA REGENERATIVA SA
Portugal
Aportación de la UE
€ 1 053 415,50
Dirección
Parque De Ciencia E Tecnologia Avepark Zona Industrial Da Gandra
4805-017 Barco Gmr

Ver en el mapa

Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
Celia Pinto (Dr.)
NAMSA
Francia
Aportación de la UE
€ 513 550
Dirección
Chemin De L Islon 115
38670 Chasse Sur Rhone

Ver en el mapa

Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
Eleonore Puissant (Dr.)
OBELIS SA
Bélgica
Aportación de la UE
€ 499 887,50
Dirección
Boulevard General Wahis 53
1030 Bruxelles

Ver en el mapa

Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
Doram Elkayam (Mr.)